CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 840 enrolled
Drug / intervention
bicalutamide +2 moredrug
Likely dose
Bicalutamide 150 mg orally once daily for 2 years; Radiation therapy 64.8 Gy in 36 fractions (1.8 Gy daily, 5 days/week)AI-extracted
Key inclusion· 8
  • Prior radical prostatectomy with pelvic lymphadenectomy for pT3N0 prostate cancer, or pT2 pN0 with positive inked resection margin, at least 12 weeks before entry
  • PSA between 0.2 and 4.0 ng/mL at entry
  • No clinical evidence of disease on physical exam or imaging
  • Bone scan within 16 weeks prior to entry showing no metastatic disease
Key exclusion· 8
  • Pathologic stage pT2 without positive inked resection margin (unless biopsy-proven recurrence)
  • Pathologic lymph node stage pN1 or greater
  • PSA >4.0 ng/mL at entry
  • Prior hormonal therapy after prostatectomy

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002874
NCT00002874Phase 3Completed

A PHASE III TRIAL OF RADIATION THERAPY WITH OR WITHOUT CASODEX IN PATIENTS WITH PSA ELEVATION FOLLOWING RADICAL PROSTATECTOMY FOR pT3N0 CARCINOMA OF THE PROSTATE

Radiation Therapy Oncology Group·interventional·Posted Jan 27, 2003·Updated Jun 15, 2022

In Brief

A Phase 3 clinical trial evaluating bicalutamide, radiation therapy, and 1 other intervention for Prostate Cancer. Completed, enrolled 840 participants across 240 sites in 2 countries.

Detailed Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using bicalutamide may fight prostate cancer by reducing the production of androgens. It is not yet known if radiation therapy is more effective with or without bicalutamide for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without bicalutamide in treating patients who have stage II or stage III prostate cancer and elevated prostate-specific antigen (PSA) levels following radical prostatectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesCanada, United States

Timeline

Phase 3CompletedFinished
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartFeb 1, 1998
Primary CompletionAug 1, 2015
Study CompletionMay 20, 2022
TodayJul 2, 2026
Enrollment to primary: 17.5 yearsPosted 23.4 years ago

Interventions

bicalutamidedrug

One (150 mg) tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.

radiation therapyradiation

64.8 Gy in 36 fractions (1.8 Gy in 5 daily sessions per week) to the original prostate volume, the tumor resection bed, and the proximal membranous urethra.

placebodrug

One tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.